TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03298594

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: specific cervicograph
Study: NCT01635192

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3
Description: The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.~Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.
Study: NCT03238508

Intervention type: PROCEDURE
Intervention: Deferred stenting
Description: Previously described
Study: NCT02345382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atuveciclib, BAY1143572
Description: The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atuveciclib, BAY1143572
Description: The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atuveciclib, BAY1143572
Description: The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atuveciclib, BAY1143572
Description: The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atuveciclib, BAY1143572
Description: The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atuveciclib, BAY1143572
Description: The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
Study: NCT02483546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laerdal®
Description: simulation- based educational intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: huma patient based training
Description: Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditionally teaching
Description: Control group students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
Study: NCT01307800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally
Study: NCT01546454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol-Levonorgestrel combination
Description: 0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
Study: NCT02345382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atuveciclib, BAY1143572
Description: The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
Study: NCT01546454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: single 22.5 mg subcutaneous depot suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: single 22.5 mg subcutaneous depot suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: single 22.5 mg subcutaneous depot suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 0.05 to 0.3 mg transdermal daily for 26 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 0.05 to 0.3 mg transdermal daily for 26 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 50 to 100 mg vaginal suppositories twice daily for 13 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 50 to 100 mg vaginal suppositories twice daily for 13 days
Study: NCT00535665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: two-dose regimen with 14 days apart: 5 microgram per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: two-dose regimen with 28 days apart: 5 microgram per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: two-dose regimen with 28 days apart: 10 microgram per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: two-dose regimen with 28 days apart: 15 microgram per dose
Study: NCT03834454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
Study: NCT04312360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic endoscopy with metronidazole and fosfomycin disodium
Description: therapeutic endoscopy where the two drugs: metronidazole and fosfomycin disodium are sprayed through out the right colon section (from caecum to right colon flexure). This intervention is going to be performed on patients in both track 1 and track 2a.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic endoscopy with metronidazole and fosfomycin disodium
Description: therapeutic endoscopy where the two drugs: metronidazole and fosfomycin disodium are sprayed through out the right colon section (from caecum to right colon flexure). This intervention is going to be performed on patients in both track 1 and track 2a.
Study: NCT03676595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive video game-based exercise
Description: Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive video game-based exercise
Description: Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no exercise
Description: Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no exercise
Description: Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
Study: NCT03240250

Intervention type: PROCEDURE
Intervention: VATS uni-portal lobectomy and lymphoadenectomy
Description: VATS uni-portal lobectomy and lymphoadenectomy

Intervention type: PROCEDURE
Intervention: VATS three-portal lobectomy and lymphoadenectomy
Description: VATS three-portal lobectomy and lymphoadenectomy, Copenhagen approach
Study: NCT03568253

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries treatment
Description: Treatment by Bulk fil composite after randomization of the tooth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries treatment
Description: Treatment by High viscosity glass ionomer after randomization of the tooth
Study: NCT01170065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Intermediate dose BIBF 1120 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: High dose BIBF 1120 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Low dose BIBF 1120 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Low dose BIBF 1120 once daily
Study: NCT03730961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous administration
Study: NCT03241771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Naloxone Navigator 1.0
Description: Patients on chronic opioid therapy will be outreached via email, mail and phone. Within 1 month of enrollment into the trial, intervention participants will receive a link to the web-based resource to view. This is designed to provide overdose education, increase opioid risk awareness, and encourage patients to obtain naloxone.
Study: NCT01913028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9929
Description: 1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
Study: NCT03005301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intelligent electroacupuncture instrument
Description: Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~Trial instrument of this study is the CX-DZ-Ⅱ type intelligent electroacupuncture therapeutic instrument.Choice of acupuncture needle: one-off stainless acupuncture needle, which is 25\~40mm in length and 0.30\~0,38mm in diameter.Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.Treatment time: each treatment time is 30 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hwato electroacupuncture instrument
Description: Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~The Hwato electroacupuncture treatment instrument. Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.~Treatment time: each treatment time is 30 minutes.
Study: NCT04332939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: real tDCS sessions

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical exercise
Description: Aerobic exercise and physical training combined with sham tDCS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Aerobic exercise and physical training combined with sham tDCS
Study: NCT03897296

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High resolution anorectal manometry, water perfused catheter
Description: High resolution anorectal manometry with the use of water-perfused catheter will be performed to eligible subjects willing to participate in the study
Study: NCT03065101

Intervention type: DEVICE
Group type: OTHER
Intervention: Trigen Intertan
Description: While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.

Intervention type: OTHER
Group type: OTHER
Intervention: Post-Surgery Follow Up
Description: The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.

Intervention type: OTHER
Group type: OTHER
Intervention: Post-Surgery Follow Up
Description: The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sliding Hip Screw
Description: Sliding Hip Screw
Study: NCT00326989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary stem cell therapy
Description: extracorporal shock waves prior to intracoronary cell therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary stem cell therapy
Description: extracorporal shock waves prior to intracoronary cell therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary stem cell therapy
Description: extracorporal shock waves prior to intracoronary cell therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary stem cell therapy
Description: extracorporal shock waves prior to intracoronary cell therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary stem cell therapy
Description: extracorporal shock waves prior to intracoronary cell therapy
Study: NCT01288469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: One subcutaneous (SC) injection in the abdomen only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: One subcutaneous (SC) injection in the abdomen only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: One SC injection in the abdomen only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Over-encapsulated tablet orally once daily in the evening with dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Over-encapsulated tablet orally once daily in the evening with dinner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Over-encapsulated tablet orally once daily in the evening with dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for atorvastatin)
Description: One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
Study: NCT01680523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical hysterectomy
Description: Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tailored adjuvant therapy
Description: After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Primary chemoradiation therapy
Description: Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
Study: NCT04014842

Intervention type: DEVICE
Group type: OTHER
Intervention: RapidShock
Description: Use of the Reconfirmation Analysis Mode algorithm
Study: NCT02689024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Local anesthetic: amide group ATC code N01BB01

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone
Description: Analgesic drug: Pyrazolone derivate with analgetic, antipyretic and antiphlogistic properties ATC N02BB02 Usual dosage is 1000 mg t.i.d. or q.i.d. orally and intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Opioids: Natural opium alkaloid. Longer-acting opioid. ATC code N02AA01 Usual dosage is 0.1 mg intravenously and titrated guided by pain and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Local anesthetic: amide group ATC code N01BB10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetic: amide group ATC code N01BB09
Study: NCT01831999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RecoveryTrack - Extended Care (RT-E)
Description: Counselors in this condition will be trained on the RecoveryTrack-Extended Care (RT-E) web-based monitoring system so that they are able to navigate the computer application, and implement the clinical content and procedures of the intervention. Counselors will conduct monitoring and feedback sessions using RT-E for clients newly admitted to IOP over a course of eight months. If the client is not attending treatment, counselors will attempt contact over the phone and via other methods. When contacted, the counselor will conduct the RT-E assessment and, as the situation warrants, provide support to reengage the client in treatment or support recovery in other ways mentioned. HIV risk will be assessed as well, with encouragement of testing and referral to HIV specialists as needed.
Study: NCT00548925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-894
Description: 6 mg BID tablets, 8 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: BID tablets, 8 weeks of treatment